Compare · EW vs GCP
EW vs GCP
Side-by-side comparison of Edwards Lifesciences Corporation (EW) and GCP Applied Technologies Inc. (GCP): market cap, price performance, sector, and recent activity on the wire.
Summary
- EW operates in Health Care, while GCP operates in Consumer Discretionary - the two are in different parts of the market.
- EW is the larger of the two at $65.47B, about 27.9x GCP ($2.35B).
- EW has hit the wire 5 times in the past 4 weeks while GCP has been quiet.
- EW has more recent analyst coverage (25 ratings vs 0 for GCP).
- Company
- Edwards Lifesciences Corporation
- GCP Applied Technologies Inc.
- Price
- $84.16+5.54%
- $32.01+0.06%
- Market cap
- $65.47B
- $2.35B
- 1M return
- +1.83%
- -
- 1Y return
- +11.37%
- -
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NYSE
- NYSE
- IPO
- 2016
- News (4w)
- 5
- 0
- Recent ratings
- 25
- 0
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
GCP Applied Technologies Inc.
GCP Applied Technologies Inc. produces and sells specialty construction chemicals and specialty building materials worldwide. Its Specialty Construction Chemicals segment offers concrete admixtures under the CONCERA, CLARENA, ADVA, CLARENA RC40, STRUX, MIRA, TYTRO, POLARSET, ECLIPSE, DARACEM, DARASET, DCI, RECOVER, WRDA, and ZYLA brands; admixtures for decorative concrete under the PIERI brand; concrete production management and control systems under the VERIFI brand; engineered concrete slab systems under the DUCTILCRETE brand; and cement additives under the OPTEVA HE, TAVERO VM, CBA, SYNCHRO, HEA2, TDA, and ESE brands. The company's Specialty Building Materials segment provides building envelope products to protect structures from water, and manages air and vapor transmission through building walls under the BITUTHENE, PREPRUFE, ADPRUFE, HYDRODUCT, ADCOR, SILCOR, PERM-A-BARRIER, ELIMINATOR, RIW, and INTEGRITANK brands; and residential building products comprising specialty roofing membranes and flexible flashings under the ICE & WATER SHIELD, TRI-FLEX, ULTRA, and VYCOR brands. This segment also offers fire protection products under the MONOKOTE brand; chemical grouts for repair and remediation in waterproofing and soil stabilization applications under the DE NEEF, HYDRO ACTIVE, SWELLSEAL, and DE NEEF PURe brands; cementitious grouts and mortars for under filling and gap filling purposes under the BETEC brand; and specialty flooring products, such as flooring moisture barriers and installation products under the KOVARA and ORCON brands. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Latest EW
- Edwards Lifesciences Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Edwards Lifesciences Reports First Quarter Results
- Edwards Lifesciences to Host Earnings Conference Call on April 23, 2026
- SEC Form 4 filed by Ullem Scott B.
- SEC Form 4 filed by Lippis Daniel J.
- SEC Form 4 filed by Bobo Donald E Jr
- Edwards Lifesciences upgraded by Wolfe Research with a new price target
- Two Year Data on Edwards Lifesciences' EVOQUE System Continue to Demonstrate Significant and Sustained Patient Benefits
- Amendment: SEC Form SCHEDULE 13G/A filed by Edwards Lifesciences Corporation
- SEC Form DEFA14A filed by Edwards Lifesciences Corporation
Latest GCP
- SEC Form 15-12G filed by GCP Applied Technologies Inc.
- SEC Form 4: Standard Latitude Fund Lp disposed of $163,641,728 worth of shares (5,113,804 units at $32.00)
- SEC Form 4: Dalbergia Investments Llc disposed of $405,265,536 worth of shares (12,664,548 units at $32.00)
- SEC Form SC 13D/A filed by GCP Applied Technologies Inc. (Amendment)
- SEC Form SC 13D/A filed by GCP Applied Technologies Inc. (Amendment)
- SEC Form 4: Feld Peter A returned $209,865,472 worth of shares to the company (6,558,296 units at $32.00), closing all direct ownership in the company
- SEC Form 4: Campos David returned $603,968 worth of shares to the company (18,874 units at $32.00) and was granted 4,903 shares, closing all direct ownership in the company
- SEC Form 4: Merrill Craig A returned $1,237,280 worth of shares to the company (38,665 units at $32.00) and was granted 18,270 shares, closing all direct ownership in the company
- SEC Form 4: Welty Linda J returned $358,752 worth of shares to the company (11,211 units at $32.00), closing all direct ownership in the company
- SEC Form 4: Yanker Robert H returned $1,776,352 worth of shares to the company (55,511 units at $32.00), closing all direct ownership in the company